Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer

作者：Luo, Guoshun; Li, Xinyu; Zhang, Guoqing; Wu, Chengzhe; Tang, Zhengpu; Liu, Linyi; You, Qidong; Xiang, Hua^*

来源：European Journal of Medicinal Chemistry, 2017, 140: 252-273.

DOI：10.1016/j.ejmech.2017.09.015

• Estrogen receptor
• VEGFR-2
• Coumarin
• Anti-breast cancer
• Docking studies

There is considerable interest in developing new SERMs as multifunctional agents in women's health. Development of dual selective estrogen receptor modulators/VEGFR-2 inhibitors (SERMs/V-2I) has been an attractive strategy for the discovery of new breast cancer therapeutic agents. Our previous efforts led to the preparation of a series of 3-aryl-4-anilino-2H-chromen-2-ones endowed with potent estrogen receptor binding affinity and anti-proliferative efficacy. In this study, various structurally related 3-aryl-4-anilino/aryloxy-2H-chromen-2-one analogues were rationally designed, synthesized and evaluated as a new chemo-type of dual ER alpha and VEGFR-2 inhibitors. Most of the derivatives exhibited potent activities in both enzymatic and cellular assays. SAR investigation revealed that introducing of bioisosteric O atom at the C-4 position of coumarin scaffold is beneficial to improve the inhibitory potency, especially in ERa binding affinity assay. Furthermore, most of the piperidyl substituted compounds showed better inhibitory activity against MCF-7 and Ishilcawa cells than lead compounds BL-18d, tamoxifen and Van-detanib. Optimization of the hit compound, identified in an ER alpha binding affinity assay, led to compound 42d, exhibiting an IC50 for Eft binding affinity of 2.19 mu M while retaining an excellent inhibition on VGFR-2 as well as a potent suppression on the growth of angiogenesis-related cells. In RT-PCR assay, 42d exerted significantly antiestrogenic property via suppressing the expression of progesterone receptor (PgR) mRNA in MCF-7 cells, which was consistent with the ER alpha antagonistic property of a selective estrogen receptor modulator. Further mechanism investigation demonstrated that compound 42d could inhibit the activation of VEGFR-2 and subsequent signaling transduction of Raf-1/MAPK/ERK pathway in MCF-7 cells. All these results together with molecular modeling studies open a new avenue for the development of multifunctional agents targeting Eft and VEGFR-2 in the therapy of some breast cancers.

• 出版日期2017-11-10
• 单位中国药科大学